Search Results - "VAN LUNZEN, Jan"

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs by Katlama, Christine, Prof, Deeks, Steven G, MD, Autran, Brigitte, Prof, Martinez-Picado, Javier, Prof, van Lunzen, Jan, Prof, Rouzioux, Christine, Prof, Miller, Michael, PhD, Vella, Stefano, MD, Schmitz, Joern E, Prof, Ahlers, Jeffrey, PhD, Richman, Douglas D, MD, Sekaly, Rafick P, Dr

“…Summary Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic…”
Get full text

Mental health and its consequences in people living with HIV: A network approach by Meeder, Elise M. G., Eekeren, Louise E. van, Blaauw, Marc J. T., Groenendijk, Albert L., Vos, Wilhelm A. J. W., Lunzen, Jan van, Joosten, Leo A. B., Netea, Mihai G., Mast, Quirijn de, Blok, Willem L., Verbon, Annelies, Berrevoets, Marvin A. H., Matzaraki, Vasiliki, Ven, Andre J. A. M. van der, Schellekens, Arnt F. A.

“…Objectives Psychiatric symptoms occur frequently in people living with human immunodeficiency virus (PLWH), which may affect quality of life, sexual risk…”
Get full text

Functional characterization of HLA-G⁺ regulatory T cells in HIV-1 infection by Li, Chun, Toth, Ilona, Schulze Zur Wiesch, Julian, Pereyra, Florencia, Rychert, Jennifer, Rosenberg, Eric S, van Lunzen, Jan, Lichterfeld, Mathias, Yu, Xu G

“…Regulatory T cells represent a specialized subpopulation of T lymphocytes that may modulate spontaneous HIV-1 disease progression by suppressing immune…”
Get full text

Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during Acute HIV-1 Infection by Streeck, Hendrik, Jessen, Heiko, Alter, Galit, Teigen, Nickolas, Waring, Mike T., Jessen, Arne, Stahmer, Ingrid, Lunzen, Jan van, Lichterfeld, Mathias, Gao, Xiaojiang, Allen, Todd M., Carrington, Mary, Walker, Bruce D., Rockstroh, Juergen K., Altfeld, Marcus

“…The immunological and virological impact of short-term treatment initiated during acute human immunodeficiency virus type 1 (HIV-1) infection was assessed…”
Get full text

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy by Rodger, Alison J, Cambiano, Valentina, Bruun, Tina, Vernazza, Pietro, Collins, Simon, van Lunzen, Jan, Corbelli, Giulio Maria, Estrada, Vicente, Geretti, Anna Maria, Beloukas, Apostolos, Asboe, David, Viciana, Pompeyo, Gutiérrez, Félix, Clotet, Bonaventura, Pradier, Christian, Gerstoft, Jan, Weber, Rainer, Westling, Katarina, Wandeler, Gilles, Prins, Jan M, Rieger, Armin, Stoeckle, Marcel, Kümmerle, Tim, Bini, Teresa, Ammassari, Adriana, Gilson, Richard, Krznaric, Ivanka, Ristola, Matti, Zangerle, Robert, Handberg, Pia, Antela, Antonio, Allan, Sris, Phillips, Andrew N, Lundgren, Jens

“…IMPORTANCE: A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral therapy (ART) as a prevention strategy is the absolute risk of…”
Get full text

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study by Clotet, Bonaventura, Dr, Feinberg, Judith, Prof, van Lunzen, Jan, Prof, Khuong-Josses, Marie-Aude, MD, Antinori, Andrea, MD, Dumitru, Irina, MD, Pokrovskiy, Vadim, Prof, Fehr, Jan, MD, Ortiz, Roberto, MD, Saag, Michael, Prof, Harris, Julia, MA, Brennan, Clare, DPT, Fujiwara, Tamio, PhD, Min, Sherene, MD

“…Summary Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and superior to a non-nucleoside reverse transcriptase inhibitor…”
Get full text

International AIDS Society global scientific strategy: towards an HIV cure 2016 by Deeks, Steven G, Lewin, Sharon R, Ross, Anna Laura, Ananworanich, Jintanat, Benkirane, Monsef, Cannon, Paula, Chomont, Nicolas, Douek, Daniel, Lifson, Jeffrey D, Lo, Ying-Ru, Kuritzkes, Daniel, Margolis, David, Mellors, John, Persaud, Deborah, Tucker, Joseph D, Barre-Sinoussi, Françoise, Alter, Galit, Auerbach, Judith, Autran, Brigitte, Barouch, Dan H, Behrens, Georg, Cavazzana, Marina, Chen, Zhiwei, Cohen, Éric A, Corbelli, Giulio Maria, Eholié, Serge, Eyal, Nir, Fidler, Sarah, Garcia, Laurindo, Grossman, Cynthia, Henderson, Gail, Henrich, Timothy J, Jefferys, Richard, Kiem, Hans-Peter, McCune, Joseph, Moodley, Keymanthri, Newman, Peter A, Nijhuis, Monique, Nsubuga, Moses Supercharger, Ott, Melanie, Palmer, Sarah, Richman, Douglas, Saez-Cirion, Asier, Sharp, Matthew, Siliciano, Janet, Silvestri, Guido, Singh, Jerome, Spire, Bruno, Taylor, Jeffrey, Tolstrup, Martin, Valente, Susana, van Lunzen, Jan, Walensky, Rochelle, Wilson, Ira, Zack, Jerome

“…The International AIDS Society Towards a Cure Working Group lays out its scientific strategy to achieve a cure for HIV. Antiretroviral therapy is not curative…”
Get full text

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis by Cutrell, Amy G., Schapiro, Jonathan M., Perno, Carlo F., Kuritzkes, Daniel R., Quercia, Romina, Patel, Parul, Polli, Joseph W., Dorey, David, Wang, Yongwei, Wu, Sterling, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L., Baker, Mark, Talarico, Christine L., Clair, Marty St, Jeffrey, Jerry, White, C. Thomas, Vanveggel, Simon, Vandermeulen, Kati, Margolis, David A., Aboud, Michael, Spreen, William R., van Lunzen, Jan

“…Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3…”
Get full text

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study by Mills, Anthony, MD, Arribas, Jose R, MD, Andrade-Villanueva, Jaime, Prof, DiPerri, Giovanni, MD, Van Lunzen, Jan, Prof, Koenig, Ellen, MD, Elion, Richard, MD, Cavassini, Matthias, MD, Madruga, Jose Valdez, MD, Brunetta, Jason, MD, Shamblaw, David, MD, DeJesus, Edwin, MD, Orkin, Chloe, MBBch, Wohl, David A, MD, Brar, Indira, MD, Stephens, Jeffrey L, MD, Girard, Pierre-Marie, Prof, Huhn, Gregory, MD, Plummer, Andrew, BS, Liu, Ya-Pei, PhD, Cheng, Andrew K, MD, McCallister, Scott, Dr

“…Summary Background Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxicity and reduced bone mineral density…”
Get full text

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial by van Lunzen, Jan, Prof, Maggiolo, Franco, MD, Arribas, José R, Prof, Rakhmanova, Aza, MD, Yeni, Patrick, Prof, Young, Benjamin, MD, Rockstroh, Jürgen K, Prof, Almond, Steve, MMath, Song, Ivy, PhD, Brothers, Cindy, MSPH, Min, Sherene, MD

“…Summary Background Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an…”
Get full text

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study by Molina, Jean-Michel, Prof, Clotet, Bonaventura, MD, van Lunzen, Jan, Prof, Lazzarin, Adriano, Prof, Cavassini, Matthias, MD, Henry, Keith, Prof, Kulagin, Valeriv, Prof, Givens, Naomi, MSc, de Oliveira, Carlos Fernando, MD, Brennan, Clare, DPT

“…Summary Background The primary analysis of the FLAMINGO study at 48 weeks showed that patients taking dolutegravir once daily had a significantly higher…”
Get full text

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 by ORTIZ, Roberto, DEJESUS, Edwin, VANGENEUGDEN, Tony, SPINOSA-GUZMAN, Sabrina, KHANLOU, Homayoon, VORONIN, Evgeniy, VAN LUNZEN, Jan, ANDRADE-VILLANUEVA, Jaime, FOURIE, Jan, DE MEYER, Sandra, DE PAUW, Martine, LEFEBVRE, Eric

“…The present primary analysis of AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS) compares the efficacy and safety of once-daily…”
Get full text

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with Progressive Disease by SCHULZE ZUR WIESCH, Julian, THOMSSEN, Adriana, DEGEN, Olaf, MAUSS, Stefan, ROCKSTROH, Jürgen, STASZEWSKI, Schlomo, KHAYKIN, Pavel, STRASAK, Alexander, LOHSE, Ansgar W, FÄTKENHEUER, Gerd, HAUBER, Joachim, VAN LUNZEN, Jan, HARTJEN, Philip, TOTH, Ilona, LEHMANN, Clara, MEYER-OLSON, Dirk, COLBERG, Kristina, FRERK, Sebastian, BABIKIR, Dalia, SCHMIEDEL, Stefan

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progression by Eberhard, Johanna Maria, Hartjen, Philip, Kummer, Silke, Schmidt, Reinhold E, Bockhorn, Maximilian, Lehmann, Clara, Balagopal, Ashwin, Hauber, Joachim, van Lunzen, Jan, Schulze zur Wiesch, Julian

“…Mucosal-associated invariant T (MAIT) cells are characterized by the combined expression of the semi-invariant T cell receptor (TCR) Vα7.2, the lectin receptor…”
Get full text

MyD88-Dependent Immune Activation Mediated by Human Immunodeficiency Virus Type 1-Encoded Toll-Like Receptor Ligands by Meier, Angela, Alter, Galit, Frahm, Nicole, Sidhu, Harlyn, Li, Bin, Bagchi, Aranya, Teigen, Nickolas, Streeck, Hendrik, Stellbrink, Hans-Juergen, Hellman, Judith, van Lunzen, Jan, Altfeld, Marcus

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Down‐regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression by Kim, Eun‐Seong, Ackermann, Christin, Tóth, Ilona, Dierks, Patrick, Eberhard, Johanna M., Wroblewski, Raluca, Scherg, Felix, Geyer, Matthias, Schmidt, Reinhold E, Beisel, Claudia, Bockhorn, Maximilian, Haag, Friedrich, Lunzen, Jan, Schulze zur Wiesch, Julian

“…Down‐regulation of CD73 on B cells of viremic HIV patients correlates with B cell activation and disease progression. Recently, alterations of the T cell…”
Get full text

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption by Rockstroh, Jürgen K, Asmuth, David, Pantaleo, Giuseppe, Clotet, Bonaventura, Podzamczer, Daniel, van Lunzen, Jan, Arastéh, Keikawus, Mitsuyasu, Ronald, Peters, Barry, Silvia, Nozza, Jolliffe, Darren, Ökvist, Mats, Krogsgaard, Kim, Sommerfelt, Maja A

“…Vacc-4x, a therapeutic HIV vaccine candidate has previously induced a significant reduction in viral load (VL) set-point compared to placebo upon interruption…”
Get full text

The Architecture of Circulating Immune Cells Is Dysregulated in People Living With HIV on Long Term Antiretroviral Treatment and Relates With Markers of the HIV-1 Reservoir, Cytomegalovirus, and Microbial Translocation by Van de Wijer, Lisa, van der Heijden, Wouter A, Ter Horst, Rob, Jaeger, Martin, Trypsteen, Wim, Rutsaert, Sofie, van Cranenbroek, Bram, van Rijssen, Esther, Joosten, Irma, Joosten, Leo, Vandekerckhove, Linos, Schoofs, Till, van Lunzen, Jan, Netea, Mihai G, Koenen, Hans J P M, van der Ven, André J A M, de Mast, Quirijn

“…Long-term changes in the immune system of successfully treated people living with HIV (PLHIV) remain incompletely understood. In this study, we assessed 108…”
Get full text

Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection by JUNG, Norma, LEHMANN, Clara, RUBBERT, Andrea, KNISPEL, Meike, HARTMANN, Pia, VAN LUNZEN, Jan, STELLBRINK, Hans-Juergen, FAETKENHEUER, Gerd, TAUBERT, Dirk

“…Carrier-mediated transport across cell membranes is an important determinant of activity, resistance, and toxicity of chemotherapeutic agents including…”
Get full text

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients by Wyen, Christoph, Hendra, Heidy, Vogel, Martin, Hoffmann, Christian, Knechten, Heribert, Brockmeyer, Norbert H., Bogner, Johannes R., Rockstroh, Jürgen, Esser, Stefan, Jaeger, Hans, Harrer, Thomas, Mauss, Stefan, van Lunzen, Jan, Skoetz, Nicole, Jetter, Alexander, Groneuer, Christiane, Fätkenheuer, Gerd, Khoo, Saye H., Egan, Deirdre, Back, David J., Owen, Andrew

“…Objectives The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and…”
Get full text